Tiziana Life Sciences reveals positive clinical, PET scan findings for intranasal Foralumab in MS patients
- Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that positive findings have been seen in a total of six out of eight Intermediate Size Patient Population Expanded Access (EA) patients, which have shown improvements in fatigue scores measured by the Modified Fatigue Impact Scale (MFIS). The clinical-stage biopharmaceutical company said PET scan findings showing a reduction in microglial activation was also seen in the six patients with MFIS score improvement at the three-month evaluation period.
- 01/08/2024
|
Tiziana Life Sciences to Present at Biotech Showcase Conference in San Francisco, January 8-10, 2024
- NEW YORK, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies, today announced that its Chief Operating Officer and Chief Medical Officer, Matthew Davis, MD, RPh, will present at Biotech Showcase, San Francisco, January 8-10, 2024.
- 01/05/2024
|
Tiziana Life Sciences files patent for foralumab combination therapy for obesity-associated inflammation
- Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has filed a new patent application relating to the composition and methods for combining a GLP-1 receptor agonist (ra) and foralumab, its lead drug candidate, to further reduce system and vascular inflammation associated with Type 2 diabetes (T2D) and also in patients with non-T2D obesity. The company said that the patent application describes the potential for foralumab, which is a fully human anti-CD3 antibody, to provide additional risk reduction for heart attack, stroke, and peripheral vascular disease when combined with a GLP-1ra in this patient population.
- 01/05/2024
|
Tiziana Life Sciences doses first patient in mid-stage multiple sclerosis study
- Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that the first patient has been dosed in its Phase 2a study which is comparing two doses of its investigational therapeutic intranasal foralumab and placebo in patients with non-active secondary-progressive multiple sclerosis (na-SPMS). The trial involves six investigational centers which will recruit up to 18 patients per treatment arm.
- 12/19/2023
|
Tiziana Life Sciences to Present at the Webull LIVE! with Corporate Connect: Biotech Investment Webinar
- NEW YORK, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announces that Matthew Davis, Chief Operating Officer and Chief Medical Officer will present at the Webull LIVE! with Corporate Connect: Virtual Biotech Investment Webinar on Wednesday, December 6th at 3:00 PM ET. The presentation will be focused on Tiziana's recent clinical updates and our Phase 2 trial of intranasal foralumab, a fully human anti-CD3 monoclonal antibody, for the treatment of non-active secondary progressive multiple sclerosis (na-SPMS) and other neuroinflammatory and neurodegenerative diseases such as Alzheimer's disease.
- 12/04/2023
|
Tiziana Life Sciences advances multiple sclerosis research program with enrollment and dosing of patients
- Biotechnology firm Tiziana Life Sciences Ltd (NASDAQ:TLSA) said it had successfully enrolled and dosed four new patients with non-active secondary progressive multiple sclerosis (na-SPMS) in the Brigham and Women's Hospital, a key member of the Mass General Brigham Healthcare System Expanded Access (EA) Program. The news brings the total number of patients being followed in the EA Program to 10.
- 11/30/2023
|
Tiziana Life Sciences to Present Recent Clinical Updates at BIO-Europe in Munich, Germany, November 6-8, 2023
- NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that its Chief Operating Officer and Chief Medical Officer, Matthew Davis, MD, RPh, will present at BIO-Europe, Munich, Germany, November 6-8, 2023. The presentation will be primarily focused on the recent clinical updates of intranasal foralumab, a fully human anti-CD3 monoclonal antibody, for the treatment of non-active secondary progressive multiple sclerosis and other neuroinflammatory and neurodegenerative diseases such as Alzheimer's. Tiziana's management will also be participating in one-on-one partnering meetings throughout the conference.
- 11/01/2023
|
Tiziana Life Sciences: FDA signs off on home-based protocol fo MS treatment
- Regulators have granted approval for home-based self-administration of Intranasal Foralumab, a treatment developed by Tiziana Life Sciences Ltd (NASDAQ:TLSA). Sign-off by the US Food & Drug Administration for this approach marks a major step forward in making treatment more accessible and convenient for those grappling with the debilitating condition.
- 10/18/2023
|
Tiziana Life Sciences stock continues to climb; COO ‘excited' by recent results
- Tiziana Life Sciences Ltd (NASDAQ:TLSA) shares rose 8% to $0.86 in midday trading on Monday after the clinical-stage biopharmaceutical company revealed six-month data that showed positive clinical improvements related to Modified Fatigue Impact Scale (MFIS) scores and similar important clinical measures of physical function in foralumab-treated, non-active Secondary Progressive Multiple Sclerosis (na-SPMS) patients participating in an Expanded Access (EA) Program. Tiziana noted that numeric improvements were seen across key multiple sclerosis measures, including the Modified Fatigue Impact Scale, Expanded Disability Status Scale, Timed 25-Foot Walk test, Pyramidal Scores and NeuroQoL Fatigue scores.
- 10/16/2023
|
Tiziana Life Sciences reveals positive clinical results for MS patients treated with Foralumab
- Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced six-month data showing positive clinical improvements related to Modified Fatigue Impact Scale (MFIS) scores and similar important clinical measures of physical function in foralumab-treated, non-active Secondary Progressive Multiple Sclerosis (na-SPMS) patients participating in an Expanded Access (EA) Program. The clinical-stage biopharmaceutical company said numeric improvements were seen across key multiple sclerosis measures, including the Modified Fatigue Impact Scale, Expanded Disability Status Scale, Timed 25-Foot Walk test, Pyramidal Scores and NeuroQoL Fatigue scores.
- 10/16/2023
|
Tiziana Life Sciences' Matthew Davis discusses significance of latest MS treatment data
- In an exclusive interview with Thomas Warner from Proactive, Matthew Davis, the chief medical officer and chief operating officer of Tiziana Life Sciences Ltd (NASDAQ:TLSA), discussed the company's latest six-month PET scan data for treating non-active secondary progressive multiple sclerosis (MS). The data show improvements in five out of six patients, supporting the drug's hypothesis published in the Proceedings of the National Academy of Science.
- 10/16/2023
|
Tiziana Life Sciences reveals positive PET scan results with Foralumab to treat MS patients
- Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that a reduction in activated microglia, as seen in six-month Positron Emission Tomography (PET) scans, has now been observed in a total of five of the six patients with non-active secondary-progressive multiple sclerosis (na-SPMS) treated with intranasal Foralumab in its Expanded Access Program (EAP). The clinical-stage biopharmaceutical company said activated microglia are believed to play a prominent role in the pathogenesis of neuroinflammatory and neurodegenerative diseases including multiple sclerosis (MS), Alzheimer's disease, and amyotrophic lateral sclerosis, or ALS.
- 10/13/2023
|
Tiziana Life Sciences to present MS treatment at ECTRIMS Annual Congress
- Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced that a late breaking poster titled, "Treatment Of Six Non-Active Secondary Progressive MS With Nasal Anti-CD3 Monoclonal Antibody (Foralumab): Safety, Biomarker, And Disability Outcomes," will be presented at the 39th Congress of the European Committee for Treatment and Research of Multiple Sclerosis (ECTRIMS) being held in Milan, Italy, from October 11-13, 2023. The clinical-stage biopharmaceutical company said ECTRIMS is a non-profit organization that serves as Europe's and the world's largest professional organization dedicated to the understanding and treatment of MS.
- 10/11/2023
|
Tiziana Life Sciences initiates multi-center Phase 2a clinical trial of intranasal foralumab for na-SPMS
- Tiziana Life Sciences Ltd (NASDAQ:TLSA) said it has commenced site initiation for its lead intranasal foralumab program entering Phase 2a clinical testing in non-active Secondary Progressive Multiple Sclerosis (na-SPMS) patients. Following an investigator's meeting with principal investigators at Brigham and Women's Hospital, a founding member of Mass General Brigham Healthcare System, the biotechnology company announced in a statement that six to 10 new clinical trial sites will be recruited, in total.
- 09/26/2023
|
Tiziana Life Sciences to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
- NEW YORK, Sept. 08, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that the Company will virtually present and host one-on-one meetings at the H.C. Wainwright 25th Annual Global Investment Conference, being held September 11-13, 2023.
- 09/08/2023
|
Tiziana Life Sciences highlights publication of promising intranasal foralumab in Alzheimer's study results
- Tiziana Life Sciences Ltd (NASDAQ:TLSA) said a study validating the mechanism of action of its drug candidate intranasal foralumab in Alzheimer's Disease has been published in the prestigious journal Proceedings of the National Academy of Sciences (PNAS). The company noted that the publication, “Nasal Administration of anti-CD3 monoclonal antibody (mAb) ameliorates disease in a mouse model of Alzheimer's disease”, is the second related to the intranasal administration of anti-CD3 monoclonal antibody to be published in PNAS this year.
- 09/06/2023
|
Tiziana Life Sciences investigational therapeutic foralumab in the spotlight at neuroimmunology event
- Tiziana Life Sciences Ltd (NASDAQ:TLSA) said its investigational therapeutic foralumab will be highlighted by its scientific advisory board chairman Dr. Howard Weiner during an oral presentation at the 16th International Society of Neuroimmunology (ISNI) Congress in Quebec City, Canada.
- 08/23/2023
|
Tiziana Life Sciences shares skyrocket after FDA greenlights intranasal foralumab for Alzheimer's disease
- Tiziana Life Sciences Ltd (NASDAQ:TLSA) shares added almost 55% in pre-market trading on Tuesday after the biotechnology company announced that its Investigational New Drug (IND) application for intranasal foralumab to be studied in Alzheimer's disease has been approved by the United States Food and Drug Administration (FDA). The company said foralumab is a “potentially groundbreaking” treatment for Alzheimer's because it targets the disease's underlying pathology by addressing the resulting neuroinflammation caused by the accumulation of toxic proteins in the brain.
- 08/15/2023
|
Tiziana Life Sciences' stock soars 41% premarket after FDA clear path for trial of intranasal treatment for Alzheimer's disease
- Tiziana Life Sciences Ltd.'s stock TLSA soared 41% in premarket trade Tuesday, after the microcap biotech said it has received clearance from Food and Drug Administration for its investigational new drug application for intranasal foralumab, a treatment for Alzheimer's disease.
- 08/15/2023
|
Tiziana promotes chief medical officer Dr Matthew Davis to chief operating officer
- Tiziana Life Sciences Ltd (NASDAQ:TLSA) said it has appointed chief medical officer Dr Matthew Davis as its new chief operating officer. With the additional role, Tiziana said Davis will further drive the company's growth and strategic initiatives under its executive chairman, founder and interim CEO Gabriele Cerrone.
- 06/13/2023
|
Tiziana Life Sciences finds promising indicator of MS treatment success
- Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced a significant update regarding non-active secondary progressive multiple sclerosis (SPMS) patients treated with h intranasal foralumab in the company's expanded access program. A reduction in microglial activation, which is associated with lowered inflammation in the brain, has now been found in five of six patients in three-month PET scans.
- 06/05/2023
|
Tiziana shares positive findings on intranasal foralumab in treating intracerebral hemorrhage
- Tiziana Life Sciences Ltd (NASDAQ:TLSA) reported promising in-depth findings on the utility of its lead candidate, intranasal foralumab, which is the only fully human anti-CD3 monoclonal antibody (mAb), in the treatment of intracerebral hemorrhage (ICH), a subtype of stroke. The New York-based biopharmaceutical company said the data using a mouse model of collagenase-induced ICH was shared in a presentation at the Annual American Academy of Neurology conference.
- 04/27/2023
|
Tiziana Life Sciences provides update on development pipeline
- Tiziana Life Sciences has updated investors on its lead programs in development along with the release of its financial results for the year ended December 31, 2022. The biotechnology company's interim CEO Gabriele Cerrone said that, after it announced in late 2022 its near-term focus on advancing intranasal foralumab to address central nervous system-mediated inflammatory diseases, Tiziana has started this year with a stream of continuous, positive program-related developments.
- 04/26/2023
|
Tiziana Life Sciences to develop Foralumab for type 1 diabetes
- Tiziana Life Sciences Ltd (NASDAQ:TLSA) (Tiziana Life Sciences Ltd (NASDAQ:TLSA)) has announced the initiation of a program to develop intranasal Foralumab as a treatment or prevention method for type 1 diabetes. The move comes after the US Food & Drug Administration approved the humanized anti-CD3 monoclonal antibody, TZIELD (teplizumab-mzwv), a new injected drug for the condition.
- 04/18/2023
|
Tiziana Life Sciences plans to investigate intranasal foralumab for the treatment of Long COVID
- Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced plans to investigate intranasal foralumab for the treatment of Long COVID, work which is supported by foralumab's well-established role in de-activating microglia cells, a key component in the pathogenesis of the disease. “We anticipate entering into a Phase 2a placebo-controlled clinical trial upon successful feedback from the FDA”, commented Dr Matthew W.
- 04/13/2023
|
Tiziana Life Sciences says intranasal foralumab presented at ‘Preserving the Brain' scientific conference and exhibit in Shanghai
- Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced that poster presentations on intranasal foralumab are being presented at the ‘Preserving the Brain' scientific conference and exhibit at the Fondazione Prada Rong Zhai in Shanghai, China. The company explained that ‘Preserving the Brain' is a scientific forum and exhibit on neurodegenerative diseases as part of the ‘Human Brains' neuroscience project.
- 04/10/2023
|
Tiziana Life Sciences reports positive data on intranasal anti-CD3 mAb in intracerebral hemorrhage
- Tiziana Life Sciences Ltd (NASDAQ:TLSA) has reported “exciting” pre-clinical data on the effects of intranasal anti-CD3 monoclonal antibody (mAb) in a model of intracerebral hemorrhage (hemorrhagic stroke), demonstrating a behavioral outcome improvement at one month. “Less than 10% of people who have hemorrhagic stroke completely recover, and most are left with a disability that could include lasting effects on their speech and physical function.
- 04/04/2023
|
Tiziana Life Sciences says anti-CD3 mAb research for treatment of Alzheimer's disease to be presented at international conference
- Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced that positive data from a study of intranasal anti-CD3 monoclonal antibody (mAb) in an animal model of Alzheimer's disease will be presented at an international conference this weekend. It said Dr Howard Weiner, who is chairman of Tiziana's Scientific Advisory Board, will present the data on April 1, 2023, at the AD/PD 2023 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders in Gothenburg, Sweden.
- 03/31/2023
|
Tiziana Life Sciences plans to accept US FDA recommendations and start Phase 2 study in Q3 2023
- Tiziana Life Sciences Ltd (NASDAQ:TLSA) said it has received feedback based on the US Food and Drug Administration (FDA) Type C meeting minutes related to the Phase 2 clinical trial of intranasal foralumab in patients with non-active Secondary Progressive Multiple Sclerosis (SPMS). Tiziana said it plans to accept the FDA's recommendations and intends to start a Phase 2 study in the third quarter of 2023 as previously announced.
- 03/28/2023
|
Tiziana Life Sciences receives positive coverage on foralumab in Forbes article
- Tiziana Life Sciences Ltd (NASDAQ:TLSA). said it has received positive coverage in an article on Forbes which highlighted foralumab, its unique intranasal monoclonal antibody currently in clinical development to treat multiple sclerosis and other neurodegenerative diseases.
- 03/17/2023
|
Tiziana Life Sciences hails publication in science journal of article on mechanism of action for intranasal foralumab
- Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced a publication in the preeminent journal Proceedings of the National Academy of Sciences (PNAS) that illustrates the immunological basis of the mechanism of action (MoA) for intranasal foralumab. In a statement, Howard L Weiner, M.D.
- 03/08/2023
|
Tiziana Life Sciences says IND filed for Phase 2 study of milciclib in combination with gemcitabine for non-small cell lung cancer
- Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced the Investigational New Drug (IND) application filing for its milciclib treatment in combination with gemcitabine for non-small cell lung cancer (NSCLC). The company said the Phase 2 IND filing, which was achieved with minimal additional resource deployment, enhances the asset value and its optionality for milciclib.
- 01/04/2023
|
Tiziana Life Sciences hails more improvements in MS patient after 11 months dosing with intranasal foralumab
- Tiziana Life Sciences Ltd (NASDAQ:TLSA) has hailed news of an improvement in a multiple sclerosis patient being treated with intranasal foralumab in a clinical study. This second expanded access patient (EA2), who has non-active secondary progressive multiple sclerosis (SPMS), has shown further improvements since last reported in September last year, according to the US Food & Drug Administration (FDA) recognised Expanded Disability Status Scale (EDSS).
- 01/03/2023
|
Tiziana Life Sciences ups R&D spend in first half of 2022 as it advances its next-generation therapeutics
- Tiziana Life Sciences Ltd (NASDAQ:TLSA) highlighted milestones from the first six months of 2022 as the company advances its pipeline of next-generation therapeutics and diagnostics for oncology and immune diseases of high unmet demand. In its interim results for the six months to June 30, 2022, the company's R&D expenses increased from $5.6 million in the first half of 2021 to $7.5 million which it attributed to the advancement of Tiziana's proprietary programs TZLS-401 and TZLS-501.
- 12/28/2022
|
Tiziana Life Sciences reveals successful completion of intranasal foralumab pre-clinical safety study
- Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced completion of the in-life portion of a 13-week, Good Laboratory Practice (GLP) foralumab intranasal pre-clinical study in transgenic HuGEMM CD3 mouse models. The clinical-stage biopharmaceutical company said the study showed that intranasal foralumab administered to the transgenic mice at doses up to 50 microgram (µg) per rodent was clinically well tolerated.
- 12/15/2022
|
Tiziana Life Sciences Announces Date of Annual General Meeting 2022
- NEW YORK, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announced that the 2022 Annual General Meeting of the Company will be held on December 29, 2022. The record date for voting at the Annual General Meeting is set as November 30, 2022. The notice, agenda and associated material have been despatched to shareholders via mail and the notice, agenda and related financial statements in the form of the relevant Form 20-F filing are available on the Company's website at https://ir.tizianalifesciences.com/shareholder-services/annual-general-meeting and https://ir.tizianalifesciences.com/financial-information/annual-reports respectively.
- 12/06/2022
|
Tiziana Life Sciences publishes peer-reviewed research, showing intranasal administered drug for autoimmune diseases is safe in humans
- Tiziana Life Sciences Ltd (NASDAQ:TLSA) said it has published a scientific article in the peer-reviewed journal Frontiers in Immunology, showing a favorable safety profile for intranasally administered foralumab and immunological activity in humans. Entitled “Nasal administration of anti-CD3 monoclonal antibody modulates effector CD8+ T cell function and induces a regulatory response in T cells in human subjects”, the findings support Tiziana's intranasal foralumab monoclonal antibody platform as a new modality for treating autoimmune and central nervous system (CNS) diseases.
- 11/23/2022
|
Is Your 60/40 Portfolio Failing? GraniteShares Offers Help
- High conviction is what it takes to build and launch the best ETFs at GraniteShares. And that's a solution for disappointing 60/40 portfolios.
- 11/04/2022
|
Tiziana Life Sciences starts enrollment of first patient cohort in program to evaluate foralumab in non-active Secondary Progressive Multiple Sclerosis patients
- Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced the start of enrollment of the first patient cohort in its intermediate-size patient population expanded access program to evaluate foralumab in non-active Secondary Progressive Multiple Sclerosis (SPMS) patients. This treatment program will evaluate dosing at the "standard" dosing of 50 mcg and, if needed, a higher 100 mcg dose of intranasal foralumab in two separate cohorts of four non-active SPMS patients each, Tiziana said.
- 10/26/2022
|
Tiziana Life Sciences plans to submit IND for phase 1 trial of intranasal foralumab in Alzheimer's disease patients by Q3 2023
- Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced that it plans to submit an Investigational New Drug Application (IND) for a phase 1 trial of intranasal foralumab in Alzheimer's disease patients. The news comes after the clinical-stage biopharmaceutical company received an affirmative written response from the US Food and Drug Administration (FDA) on a Pre-Investigational New Drug Application (PIND).
- 10/12/2022
|
Tiziana Life Sciences presents intranasal foralumab at Preserving the Brain scientific conference in Italy
- Tiziana Life Sciences Ltd (NASDAQ:TLSA) has presented posters on intranasal foralumab at the Preserving the Brain scientific conference, a scientific forum and exhibit on neurodegenerative diseases as part of human brains held at the Fondazione Prada in Milan, Italy. Further, the company said the first secondary progressive multiple sclerosis patient receiving intranasal foralumab was interviewed by Tiziana scientific advisory board chairman Howard Weiner.
- 09/28/2022
|
Tiziana Life Sciences reports continued improvements in second patient with secondary progressive multiple sclerosis after intranasal foralumab treatment
- Tiziana Life Sciences Ltd (NASDAQ:TLSA) has reported further positive results from a patient with non-active secondary progressive multiple sclerosis (SPMS) being treated with the company's intranasal foralumab (formerly NI-0401). After receiving intranasal foralumab treatment for six months, the second patient (EA2) with SPMS has shown additional clinical improvements as measured by the Expanded Disability Status Scale (EDSS), a standard clinical assessment, the company said.
- 09/20/2022
|
Tiziana Life Sciences says Brigham and Women's Hospital gets grant to explore use of intranasal anti-CD3 mAb in ALS
- Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced that Brigham and Women's Hospital (BWH) will receive a grant to explore the use of intranasal anti-CD3 monoclonal antibody (mAb) in the nervous system disease Amyotrophic Lateral Sclerosis (ALS). The company said the Lawrence & Isabel Barnett Drug Development Program Grant will be awarded to the Ann Romney Center for Neurologic Diseases at BWH by the ALS Association for the study of an intranasal anti-CD3 mAb in an animal model of ALS.
- 09/15/2022
|
Tiziana Life Sciences says study using nasal anti-CD3 (Foralumab) presented at the Alzheimer's Association International Conference
- Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced the presentation of a study entitled, 'Treatment of Alzheimer's disease by modulation of microglial neuroinflammation by nasal anti-CD3 mAb' at the Alzheimer's Association International Conference (AAIC) The company said that in the study animal models of Alzheimer's disease (AD) demonstrated that microglia activity was restored and cognition was improved following the dosing of intranasal anti-CD3 monoclonal antibody. The study was presented virtually at the AAIC by Dr Howard L.
- 08/01/2022
|
Tiziana Life Sciences appoints Dr Matthew Davis as its chief medical officer and acting chief scientific officer, effective immediately
- Tiziana Life Sciences Ltd said it has appointed Dr Matthew Davis as its chief medical officer and acting chief scientific officer, effective immediately. The company noted that Dr Davis will report to Gabriele Cerrone, executive chairman and interim chief executive officer of Tiziana.
- 07/18/2022
|
Tiziana Life Sciences Shares Jump After Multiple Sclerosis Data From Second Patient
- Tiziana Life Sciences (NASDAQ: TLSA) reported clinical results from the second patient with Secondary Progressive Multiple Sclerosis (SPMS) in the ongoing study as part of an expanded access program. These results confirm the previously reported data from the first SPMS patient after three.
- 06/08/2022
|
Tiziana Life Sciences reports positive results from second patient in multiple sclerosis study of foralumab
- Tiziana Life Sciences PLC (NASDAQ:TLSA) said a second patient with Secondary Progressive Multiple Sclerosis (SPMS) in an ongoing study has shown clinical improvements following three months of treatment with its intranasal drug foralumab. The patient showed improvements based on Positron Emission Tomography (PET) imaging analysis, a neurologic exam and a timed 25-foot walk test.
- 06/08/2022
|
Tiziana Life Sciences to Present at the 2022 Biotechnology Innovation Organization Annual Convention to Discuss Recent Updates to Ongoing Clinical Programs
- NEW YORK, June 06, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd (NASDAQ: TLSA) ("Tiziana" or the "Company"), a clinical-stage biopharmaceutical company enabling breakthrough immunotherapies via novel routes of administration today announced that its Chief Executive Officer and Chief Scientific Officer, Kunwar Shailubhai, Ph.D., will present at the Biotechnology Innovation Organization (BIO) Annual Convention taking place at the San Diego Convention Center, Monday June 13 - Thursday, June 16, 2022. His presentation will be primarily focused on the recent clinical updates on nasal administration of foralumab, a fully human anti-CD3 monoclonal antibody, for treatment of patients with secondary progressive multiple sclerosis. He will also provide an update on the initiation of Phase 1b trial with ‘first-ever' oral capsules of foralumab for treatment of patients with mild-to-moderately active Crohn's Disease. Company management will also be participating in one-on-one meetings throughout the conference.
- 06/06/2022
|
Tiziana Life Sciences receives FDA go-ahead to enroll more multiple sclerosis patients in expanded access program for treatment with intranasal foralumab
- Tiziana Life Sciences PLC (NASDAQ:TLSA) said the US Food and Drug Administration (FDA) has given permission for the enrollment of additional Secondary Progressive Multiple Sclerosis (SPMS) patients for treatment with intranasal foralumab. The company said its collaborators at the Brigham and Women's Hospital (BWH) Boston MA have received a 'Study May Proceed Letter' from the FDA to initiate treatment in up to an additional eight SPMS patients as part of an Intermediate-Size Patient Population Expanded Access Investigational New Drug (IND).
- 04/05/2022
|
Tiziana Life Sciences: Analyst shares his feedback from key opinion leader call on Foralumab
- Zak's Small Cap Research has provided its feedback from a ‘key opinion leader virtual event' hosted by Tiziana Life Sciences Ltd. The set-piece was organized after the publication of encouraging data from a trial of Tiziana's lead drug, which was used to treat a single patient with secondary progressive multiple sclerosis, an advanced form of the disease.
- 03/15/2022
|
Top Penny Stocks Today: Why PT, TLSA, AGRI and HTCR Are Up Thursday
- Penny stocks are on the move today with some of the top companies in the space seeing major movement alongside heavy trading of their shares. The post Top Penny Stocks Today: Why PT, TLSA, AGRI and HTCR Are Up Thursday appeared first on InvestorPlace.
- 03/10/2022
|
Tiziana Life Sciences CEO to Present at Annual BIO CEO & Investor Conference
- NEW YORK, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, announced today that Dr Kunwar Shailubhai, Chief Executive Officer and Chief Scientific Officer, will be presenting at the upcoming 2022 BIO CEO & Investor Conference being held at the Marriott Marquis in NYC on February 14-15 and virtually through the 17th.
- 02/10/2022
|
Tiziana Life Sciences given nod for second patient to undergo multiple sclerosis treatment
- Tiziana Life Sciences Ltd announced that the US Food and Drugs Administration (FDA) has accepted its request to enroll a second patient onto the ongoing clinical treatment of secondary progressive multiple sclerosis (SPMS). Tiziana, a biotechnology company that enables immunotherapies via novel routes of drug delivery, is evaluating nasally administered foralumab for SPMS.
- 01/10/2022
|
Tiziana Life Sciences to Participate in 2022 Biotech Showcase Virtual Investor Conference
- NEW YORK, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences (Nasdaq: TLSA) (“Tiziana”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announced that senior management will present at the Biotech Showcase Conference and be available for one-on-one meetings throughout the conference. The conference is being held virtually from January 10th -12th and also during January 17th -19th.
- 01/06/2022
|
Tiziana Life Sciences plc: Court Sanctions the Scheme of Arrangement and approves Reduction of Capital
- LONDON and NEW YORK, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS) ("Old Tiziana") a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases announced on 20 August 2021 that it had formally commenced its strategic plan to change its corporate structure by establishing Tiziana Life Sciences Ltd (“New Tiziana”), a Bermuda-incorporated company, as the ultimate parent company of the Tiziana Group. The reorganisation will be achieved by a scheme of arrangement under Part 26 of the Companies Act 2006 (the "Scheme").
- 10/19/2021
|
Tiziana Life Sciences plc: PDMR Dealing
- LONDON and NEW YORK, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that it has been notified that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman has a beneficial interest, purchased 100,000 ordinary shares of 3p each in the market at a price of 52p per share.
- 09/28/2021
|
Tiziana Life Sciences Plc - Results of Court Meeting and General Meeting
- LONDON, Sept. 27, 2021 (GLOBE NEWSWIRE) -- On 20 August 2021, Tiziana Life Sciences Plc (“Old Tiziana”) announced that it has formally commenced its strategic plan to change its corporate structure by establishing Tiziana Life Sciences Ltd (“New Tiziana”), a Bermuda-incorporated company, as the ultimate parent company of the of the Tiziana Group, to be effected by means of a scheme of arrangement under Part 26 of the Companies Act 2006 (the “Scheme”).
- 09/27/2021
|
Tiziana Life Sciences' half-term report reveals it has made progress on all fronts
- Interim results from Tiziana Life Sciences PLC (NASDAQ:TLSA, LSE:TILS, FRA:RTRA, OTC:TIZAF) revealed the significant progress made by the drug developer in the first half of the year. In the six-month period to 30 June, the group was able to provide the first early demonstration that its monoclonal antibody (mAB) treatment, Foralumab, could be administered nasally using the local and lymphatic immune systems directly.
- 09/27/2021
|
Tiziana Life Sciences half-term report reveals it has made progress on all fronts
- Interim results from Tiziana Life Sciences PLC revealed the significant progress made by the drug developer in the first six months of the year. In six month period to June 30, the group was able to provide the first early demonstration that its monoclonal antibody (mAB) treatment, Foralumab, could be administered nasally using the local and lymphatic immune systems directly.
- 09/27/2021
|
Tiziana Life Sciences plc - Interim Results for the Six Months Ended 30 June 2021
- Advancing pipeline of next generation therapeutics and diagnostics for oncology and immune diseases of high unmet need Advancing pipeline of next generation therapeutics and diagnostics for oncology and immune diseases of high unmet need
- 09/24/2021
|
Tiziana Life Sciences upbeat on potential for coronavirus treatment
- How it is doing Shares have soared recently on the potential for Tiziana's (LON:TILS) TZLS-501 to be useful for people severely ill with coronavirus-related complications. TZLS-501 is a class of monoclonal antibody (mAb) called an anti-interleukin-6 receptor, or anti-IL6R for short.
- 09/22/2021
|
Tiziana to Host Investor Call to Discuss Exclusive License Agreement to Evaluate Foralumab, a Novel, Fully Human Anti-CD3 Monoclonal Antibody, in Conjunction with Allogeneic CAR T Candidates for Cancer Treatment
- NEW YORK and LONDON, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, will host a conference call and audio webcast on Wednesday, September 8, at 4:15 p.m. ET to discuss its recently announced exclusive license agreement to evaluate Foralumab, the Company's novel, fully human anti-CD3 monoclonal antibody, in conjunction with allogenic CAR T candidates for cancer treatment.
- 09/07/2021
|
Tiziana Life Sciences plc Posting of Scheme Document and Notice of Meetings
- THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU WHICH IS PART OF DOMESTIC UK LAW PURSUANT TO THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS (SI 2019/310) ("UK MAR"). UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION (AS DEFINED IN UK MAR) IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.
- 09/03/2021
|
Tiziana Life Sciences races at US open after exclusive licensing agreement with Precision BioSciences
- Shares in Tiziana Life Sciences PLC raced 20% higher in the opening minutes of trading on Wall Street after the group inked an exclusive licensing agreement with Precision BioSciences (NASDAQ:DTIL). The tie-up takes it into the exciting arena of CAR-T therapy with the pair looking to use Tiziana's foralumab monoclonal antibody (mAb) to enhance the next generation of cancer treatments.
- 09/02/2021
|
Precision BioSciences, Tiziana Life Ink Foralumab Deal For Cancer Indications
- Precision BioSciences Inc (NASDAQ: DTIL) and Tiziana Life Sciences plc (NASDAQ: TLSA) have announced an exclusive license agreement for Tiziana's foralumab. The companies plan to explore the fully human anti-CD3 monoclonal antibody as an agent to induce tolerance of allogeneic CAR T cells.
- 09/02/2021
|
Tiziana Life Sciences surges on exclusive licensing agreement with Precision BioSciences
- Tiziana Life Sciences PLC surged 19% to 73p after signing an exclusive licensing agreement with Precision BioSciences (NASDAQ:DTIL). The pair will explore the use of Tiziana's foralumab monoclonal antibody (mAb) to enhance the next generation of CAR-T therapies.
- 09/02/2021
|
Tiziana Life Sciences inks exclusive licensing deal with US group Precision BioSciences that takes it into CAR-T therapy
- Tiziana Life Sciences PLC (NASDAQ:TLSA, LON:TILS) said it has inked an exclusive licensing agreement with Precision BioSciences (NASDAQ:DTIL) to explore the use of Tiziana's foralumab monoclonal antibody (mAb) to enhance the next generation of CAR-T therapies. CAR-T, or chimeric antigen receptors cell therapy, is at the vanguard of treating blood-borne cancers, and major acquisitions by Celgene (now owned by Bristol Myers Squibb) and Gilead Sciences (NASDAQ:GILD) underscore the interest in this emerging area of biotechnology.
- 09/02/2021
|
Precision BioSciences and Tiziana Life Sciences Announce Exclusive License Agreement to Evaluate Foralumab, a Novel, Fully Human Anti-CD3 Monoclonal Antibody, in Conjunction with Allogeneic CAR T Candidates for Cancer Treatment
- Precision Gains Access to Tiziana's Anti-CD3 Antibody, Foralumab, to Evaluate as a Lymphodepletion Agent with its Allogeneic CAR T Portfolio Precision Gains Access to Tiziana's Anti-CD3 Antibody, Foralumab, to Evaluate as a Lymphodepletion Agent with its Allogeneic CAR T Portfolio
- 09/02/2021
|
Tiziana Life Sciences set for Nasdaq move
- Tiziana Life Sciences Plc told investors it has formally begun its strategic plan to change its corporate structure. It has established a Bermuda-incorporated company Tiziana Life Sciences Ltd which is the ultimate parent company of the Tiziana Group.
- 08/20/2021
|
Tiziana Life Sciences plc files scheme of arrangement to effect a corporate reorganisation and, if approved, the delisting of its ordinary shares in London and the direct listing of common shares in the new parent company of the Tiziana group on NASDAQ
- LONDON and NEW YORK, Aug. 20, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS) ("Old Tiziana") a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases today announces that it has formally commenced its strategic plan to change its corporate structure by establishing Tiziana Life Sciences Ltd (“New Tiziana”), a Bermuda-incorporated company, as the ultimate parent company of the of the Tiziana Group. The reorganisation will be achieved by a scheme of arrangement under Part 26 of the Companies Act 2006 (the "Scheme").
- 08/20/2021
|
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Tesla, Inc. and Encourages Investors with Losses to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - August 18, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Tesla, Inc. ("Tesla" or "the Company") (NASDAQ: TLSA) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. The NHTSA opened an investigation into Tesla's Autopilot system as reported by...
- 08/18/2021
|
Tiziana Life Sciences: Peer reviewed scientific article underscores the potential of monoclonal antibody nasal spray as a take-home Covid treatment
- A peer-reviewed scientific article has underscored the potential of Tiziana Life Sciences PLC (LSE:TILS, NASDAQ:TLSA, FRA:RTRA, OTC:TIZAF)'s monoclonal antibody nasal spray in people with mild-to-moderate Covid. The report in the Frontiers in Immunology showed Foralumab produced a significant reduction in lung inflammation as assessed by a CT scan.
- 08/17/2021
|
Tiziana Life Sciences upbeat on potential for coronavirus treatment
- How it is doing Shares have soared recently on the potential for Tiziana's (LON:TILS) TZLS-501 to be useful for people severely ill with coronavirus-related complications. TZLS-501 is a class of monoclonal antibody (mAb) called an anti-interleukin-6 receptor, or anti-IL6R for short.
- 08/17/2021
|
Tiziana Life Sciences: Peer reviewed scientific article underscores the potential of monoclonal antibody nasal spray as a take-home Covid treatment
- A peer-reviewed scientific article has underscored the potential of Tiziana Life Sciences PLC's (NASDAQ:TLSA, LON:TILS) monoclonal antibody nasal spray in people with mild-to-moderate Covid. The report in the Frontiers in Immunology showed Foralumab produced a significant reduction in lung inflammation as assessed by a CT scan.
- 08/17/2021
|
Tiziana Announces Publication of a Peer Reviewed Article on Data from the Clinical Trial with Intranasally Administered Foralumab, Its Proprietary Fully Human Anti-CD3 Monoclonal Antibody, in Mild to Moderate COVID-19 Patients in Brazil
- NEW YORK and LONDON, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, announces publication of a scientific article in the peer-reviewed journal Frontiers in Immunology titled " Nasal Administration of Anti-CD3 Monoclonal Antibody (Foralumab) Reduces Lung Inflammation and Blood Inflammatory Biomarkers in Mild to Moderate COVID-19 Patients: A Pilot Study "(1). The study was completed in collaboration with scientific teams at the Harvard Medical School (Boston, USA) and INTRIALS, a full-service Latin American CRO based in São Paulo, Brazil. The aim of the study was to assess safety of intranasal Foralumab and evaluate its potential benefits in treating immune hyperactivity and lung inflammation in mild to moderate COVID-19 patients who were outpatients at the Santa Casa de Misericordia de Santos Hospital in Brazil. Thirty-nine patients were randomized into three cohorts: no Foralumab treatment (control), nasal Foralumab (100 ug) + Dexamethasone (6 mg orally on days 1-3), and nasal Foralumab (100 ug) alone administered for 10 consecutive days. All arms were allowed to continue standard of care medications. To view the online publication, please click here: http://journal.frontiersin.org/article/10.3389/fimmu.2021.709861/full?&utm_source=Email_to_authors_&utm_medium=Email&utm_content=T1_11.5e1_author&utm_campaign=Email_publication&field=&journalName=Frontiers_in_Immunology&id=709861
- 08/17/2021
|
Tiziana Life Sciences plc Invites You to Join Us at the Q3 Virtual Investor Summit
- London, United Kingdom--(Newsfile Corp. - August 16, 2021) - Tiziana Life Sciences plc (NASDAQ:TLSA) today announced that Dr. Kunwar Shailubhai, CEO & CSO will be attending the Q3 Virtual Investor Summit. Event Q3 Investor Summit Date August 17-18th, 2021 Presentation
- 08/16/2021
|
Why Tiziana Life Sciences Shares Are Trading Higher Today
- Tiziana Life Sciences (NASDAQ: TLSA) shares are trading higher by 16% at $2.10 as traders circulate a June 17 press release from the company titled 'Tiziana Responds to UK Call for Development of Innovative 'Take Home' Treatments for COVID-19 Disease.' Tiziana Life Sciences is a clinical-stage biotechnology company that specializes in developing transformative therapies for autoimmune and inflammatory diseases, degenerative diseases and cancer-related to the liver.
- 07/23/2021
|
Tiziana Life Sciences plc - ADS Ex-Dividend Date Scheduled for July 09, 2021
- THIS ANNOUNCEMENT IS FOR US ADS HOLDERS ONLY
- 07/08/2021
|
Tiziana Life Sciences plc - Distribution Dates for shares and ADRs in Accustem Sciences Limited
- LONDON and NEW YORK, July 02, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that the Forms 20-F and F-6 filed by Accustem Sciences Limited with the SEC have been declared effective, enabling the completion of the in specie distribution and spin out of Accustem Sciences Limited. These documents together can be found at www.accustem.com
- 07/02/2021
|
Dr Howard Weiner, Chairman of the Tiziana Scientific Advisory Board, to give an interview on Bloomberg Markets at 1.50pm ET today
- NEW YORK and LONDON, June 30, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, announces an interview with the Chairman of its' Scientific Advisory Board and Professor of Neurology at Harvard Medical School, Dr Howard Weiner is to air on Bloomberg Markets with Matt Miller and Amanda Lang today at 1.50pm ET/6.50pm BST.
- 06/30/2021
|
Tiziana Life Sciences plc (the "Company") Result of Annual General Meeting
- LONDON, June 25, 2021 (GLOBE NEWSWIRE) -- At the Annual General Meeting of the Company held at 10.00 a.m. on 25 June 2021, all of the resolutions were duly passed.
- 06/25/2021
|
TLSA Stock Price Increases Over 6% Pre-Market: Why It Happened
- The stock price of Tiziana Life Sciences plc (NASDAQ: TLSA) increased by over 6% pre-market. This is why it happened.
- 06/23/2021
|
Tiziana Life Sciences pulls the trigger on phase II Covid trial after appointing a contract research group
- Tiziana Life Sciences PLC (NASDAQTLSA, LON:TILS) said it has signed a deal with contract research group FHI Clinical to carry out a phase II, proof-of-concept study on its nasally-administered antibody treatment for Covid. Foralumab will be given to hospitalised patients with severe coronavirus as part of the Brazil trial that will build on earlier work in mild-to-moderate cases which confirmed the safety and tolerability of the drug as well as its potential efficacy.
- 06/23/2021
|
Tiziana Enters a Collaboration Agreement with FHI Clinical to Conduct a Phase 2 Clinical Trial for Treating Hospitalized Severe COVID-19 Patients with Intranasal Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody
- NEW YORK and LONDON, June 23, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS), ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, neurology, inflammation and infectious diseases, announces that it has signed an agreement with FHI Clinical, a global clinical contract research organization (CRO), to conduct a Phase 2 Proof-of-concept study in Brazil to evaluate the safety, tolerability and efficacy of intranasal Foralumab in hospitalized patients with severe coronavirus disease 2019 (COVID-19) and pulmonary inflammation.
- 06/23/2021
|
Tiziana Life Sciences appoints head of regulatory affairs
- Tiziana Life Sciences PLC (NASDAQ:TLSA, LON:TILS) has appointed a vice-president of regulatory affairs. Dr Kevin Shutz, who has 19 years pharma industry experience, 14 of them in the regulatory field, will lead clinical trial ‘interactions' with drug watchdogs in the US, Europe and Asia.
- 06/21/2021
|
Tiziana Appoints Dr. Kevin Schutz as Vice-President of Regulatory Affairs
- NEW YORK and LONDON, June 21, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, neurology, inflammation and infectious diseases, is pleased to announce the appointment of Dr. Kevin Schutz, PharmD, as Vice-President of Regulatory Affairs. Dr. Schutz will lead regulatory interactions related to clinical studies in the United States, Europe and Asian countries.
- 06/21/2021
|
TLSA Stock Price Increases Over 7% Pre-Market: Why It Happened
- The stock price of Tiziana Life Sciences PLC (NASDAQ: TLSA) increased by over 7% pre-market. This is why it happened.
- 06/17/2021
|
Tiziana Life Sciences seeks UK funding for 'take-home' nasal COVID-19 treatment
- Tiziana Life Sciences PLC (NASDAQ:TLSA, LON:TILS) said it applied for UK government funding for its nasally administered antibody therapy under a scheme looking for ‘take-home treatments' for sufferers of Coronavirus (COVID-19). Grants are being awarded to companies developing medicines that will prevent people with the illness from being hospitalised.
- 06/17/2021
|
Tiziana Responds to UK Call for Development of Innovative ‘Take Home' Treatments for COVID-19 Disease
- NEW YORK and LONDON, June 17, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, neurology, inflammation and infectious diseases announces that it has submitted a grant to the United Kingdom COVID Therapeutics Advisory Panel (UK-CTAP) to support further clinical development of nasally administered Foralumab, a fully human anti-CD3 monoclonal antibody, as an innovative ‘ Take Home' approach for treatment of non-hospitalized patients with COVID-19. This is in response to a call from the UK government for proposals to study therapies that can be delivered at home and avoid hospitalization of patients.
- 06/17/2021
|
Tiziana Life Sciences upbeat on potential for coronavirus treatment
- How it is doing Shares have soared recently on the potential for Tiziana's (LON:TILS) TZLS-501 to be useful for people severely ill with coronavirus-related complications. TZLS-501 is a class of monoclonal antibody (mAb) called an anti-interleukin-6 receptor, or anti-IL6R for short.
- 06/16/2021
|
Tiziana Life Sciences plc ("Tiziana" or the “Company”) Posting of Notice of Annual General Meeting
- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION.
- 06/02/2021
|
US Investment bank repeats 'buy' and US$8 price target on Tiziana Life Sciences after flurry of positive news
- Investment bank B Riley has restated its 'buy' advice and US$8 price target for shares in Tiziana Life Sciences PLC (LON:TILS) (NASDAQ:TLSA) after a flurry of positive news. It said safety data on key drug Foralumab, signs of its efficacy in COVID-19 patients and its clearance for its use in a patient with MS provided “incremental validation” of the monoclonal antibody (mAb) treatment.
- 05/28/2021
|
Zacks Small-Cap Research repeats its valuation on Tiziana Life Sciences as company starts nasally administered Foralumab trial for SPMS
- Zacks Small-Cap Research has put out a note on drug developer Tiziana Life Sciences PLC (NASDAQ:TLSA) (LON:TILS), which it started covering in April this year, repeating its valuation of US$7.50 per ADR share, compared to a current price of US$2.37. It comes after Tiziana announced, on May 25, it had begun treating a first patient with secondary progressive multiple sclerosis (SPMS) in a trial using nasally administered Foralumab - its fully-human anti-CD3 monoclonal antibody.
- 05/27/2021
|
Zacks Small-Cap Research repeats its valuation on Tiziana Life Sciences as company starts nasally administered Foralumab trial for SPMS
- Zacks Small-Cap Research has put out a note on drug developer Tiziana Life Sciences PLC (NASDAQ:TLSA) (LON:TILS), which it started covering in April this year, repeating its valuation of US$7.50 per ADR share, compared to a current price of US$2.37. It comes after Tiziana announced, on May 25, it had begun treating a first patient with secondary progressive multiple sclerosis (SPMS) in a trial using nasally administered Foralumab - its fully-human anti-CD3 monoclonal antibody.
- 05/27/2021
|
Zacks Small-Cap Research repeats its valuation on Tiziana Life Sciences as company starts nasally administered Foralumab trial for SPMS
- Zacks Small-Cap Research has put out a note on drug developer Tiziana Life Sciences PLC (NASDAQ:TLSA) (LON:TILS), which it started covering in April this year, repeating its valuation of US$7.50 per ADR share, compared to a current price of US$2.37. It comes after Tiziana announced, on May 25, it had begun treating a first patient with secondary progressive multiple sclerosis (SPMS) in a trial using nasally administered Foralumab - its fully-human anti-CD3 monoclonal antibody.
- 05/27/2021
|
Tiziana Life's Foralumab Induces Immunomodulation, Anti-Inflammatory Effects In Early-Stage Study
- Tiziana Life Sciences plc (NASDAQ: TLSA) has provided an update on further analysis of lymphocyte subsets from a Phase 1 study with nasally administered foralumab in healthy volunteers. Data showed statistically significant immunomodulatory effects on CD8 cytotoxic T-lymphocytes and other inflammatory biomarkers.
- 05/26/2021
|
Tiziana Life hails 'major accomplishment as nasally administered antibody shows potential to treat degenerative diseases such as MS
- Tiziana Life Sciences PLC (LON:TILS, NASDAQ:TLSA) said its breakthrough fully-human monoclonal antibody “induces immunomodulatory effects capable of providing clinical benefit” when administered nasally. The latest data come from a phase I assessment of Foralumab, which is being developed for a range of neurodegenerative diseases such as multiple sclerosis, amyotrophic lateral sclerosis and Alzheimer's disease.
- 05/26/2021
|
Tiziana Life PLC hails "major accomplishment" as nasally administered antibody shows potential to treat degenerative diseases such as MS
- Tiziana Life Sciences PLC (LON:TILS, NASDAQ:TLSA) said its breakthrough fully-human monoclonal antibody “induces immunomodulatory effects capable of providing clinical benefit” when administered nasally. The latest data come from a phase I assessment of Foralumab, which is being developed for a range of neurodegenerative diseases such as multiple sclerosis, amyotrophic lateral sclerosis and Alzheimer's disease.
- 05/26/2021
|
Tiziana Reports Data Indicating Significant Immunomodulation effects on Immune and Inflammatory Biomarkers with Nasally Administered Foralumab in Healthy Volunteers
- NEW YORK and LONDON, May 26, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for inflammatory diseases and cancers, today provided an update on further analysis of lymphocyte subsets from blood samples from a Phase 1 study with nasally administered Foralumab in healthy volunteers. Results exhibiting statistically significant immunomodulatory effects on CD8 cytotoxic T-lymphocytes and other inflammatory biomarkers were observed. This Phase 1 trial, conducted at the Brigham and Women's Hospital, Harvard Medical School, Boston, MA, was a single-site, double-blind, placebo-controlled, dose-ranging study with nasally administered Foralumab at 10, 50 and 250 mcg per day, consecutively for 5 days in healthy volunteers. The treatment was well-tolerated at all doses and there were no apparent symptoms of severe toxicity. Importantly, the treatment showed significant positive effects at 50 mcg/day dose (compared to other dose and placebo groups) on T-cell subsets and inflammatory biomarkers. These data support other clinical and pre-clinical studies showing that this route of administration is capable of inducing site-targeted immunomodulation and anti-inflammatory effects. Furthermore these pharmacodynamic data point to a clinical dose range that Tiziana intends to test in further clinical development among MS patients.
- 05/26/2021
|
TLSA Stock Price: Over 8% Increase Pre-Market Explanation
- The stock price of Tiziana Life Sciences PLC (NASDAQ: TLSA) increased by over 8% pre-market. This is why it happened.
- 05/25/2021
|
Tiziana Life Starts Testing Nasally Administered Foralumab in Multiple Sclerosis Patients
- Under an individual patient expanded access program, Tiziana Life Sciences plc (NASDAQ: TLSA) has dosed the first patient with secondary progressive multiple sclerosis with nasally administered foralumab. Nasal Foralumab 50 mcg (25 mcg/nostril) will be administered in 3-week cycles, three times/week dosing for the first two weeks followed by one week of a rest period.
- 05/25/2021
|
Tiziana Life Sciences initiates trial using nasally administered monoclonal antibody to treat a person with secondary progressive multiple sclerosis
- Tiziana Life Sciences PLC (LON:TILS, NASDAQ:TLSA) said it has begun treating a patient with secondary progressive multiple sclerosis using nasally-administered Foralumab, the company's fully-human anti-CD3 monoclonal antibody. The drug will be provided under the Food & Drug Administration's individual patient expanded access protocol overseen by researchers at the Brigham and Women's Hospital (BWH), Harvard.
- 05/25/2021
|
Tiziana Life Sciences Announces Initiation of Clinical Trial in a Secondary Progressive Multiple Sclerosis (SPMS) Patient with Nasal Administration of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, Under an Individual Patient Expanded Access Program
- NEW YORK and LONDON, May 25, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for inflammatory diseases and cancers, is pleased to announce that the first patient with secondary progressive multiple sclerosis (SPMS) was dosed with nasally administered Foralumab, a fully human anti-CD3 monoclonal antibody, at the Brigham and Women's Hospital (BWH), Harvard Medical School, Boston, MA. Nasal Foralumab 50 mcg (25 mcg/nostril) will be administered in 3-week cycles, with 3 times/week dosing for the first 2 weeks followed by 1 week of rest period. This first-ever clinical study in SPMS patients, under an Individual Patient Expanded Access IND, will continue for six months to evaluate routine safety, tolerability, and neurological behaviors. The study will also examine microglial activation, by positron emission tomography (PET), immunological and neurodegenerative markers to assess clinical responses following the treatment regimen.
- 05/25/2021
|
Tiziana Life Sciences confident of advancing drug development pipeline
- Tiziana Life Sciences PLC (NASDAQ:TLSA) (LON:TILS) said it is confident that it is well positioned to advance its drug development programs "to their next respective value inflection points". Final results on Tuesday showed cash of £48.2mln in the bank at the end of December, after a year when the company made a loss before tax of £21.8mln as R&D and operating costs increased as it continued to progress a pipeline of drugs to treat rare cancers and autoimmune and inflammatory diseases.
- 05/18/2021
|
Tiziana Life Sciences Interview to Air on Bloomberg Television U.S. on the RedChip Money Report
- NEW YORK and LONDON, May 07, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announced an interview with CEO and CSO Dr. Kunwar Shailubhai will air on The RedChip Money Report on the Bloomberg Network in the U.S. on Saturday, May 8 at 7 p.m. local time. The RedChip Money Report airs on Bloomberg Television U.S. on Saturdays at 7 p.m. local time in approximately 73M homes.
- 05/07/2021
|
Tiziana Life Sciences seeks clinical partner in Asia to progress work on liver cancer treatment
- Tiziana Life Sciences PLC (LON:TILS)(NASDAQ:TLSA) announced an agreement with Takanawa Japan for a strategic business development plan to identify a clinical partner in Japan and other Asian countries. The pair are looking for a company to cooperate on further clinical development of Milciclib for treatment in advanced hepatocellular carcinoma (HCC) patients.
- 05/05/2021
|
Tiziana Announces Strategic Initiative with Takanawa Japan K.K., Pharma Team, to Identify a Partner in Japan and Other Asian Countries for Further Clinical Development of Milciclib in Patients with Advanced Hepatocellular Carcinoma.
- NEW YORK and LONDON, May 05, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, announces that it has executed an agreement with Takanawa Japan K.K, Pharma Team, (Takanawa) for a strategic business development plan to Identify a clinical partner in Japan and other Asian countries for further clinical development of Milciclib for treatment in advanced hepatocellular carcinoma (HCC) patients. HCC is the most common type of liver cancer and affects approximately 200,000 people per year.
- 05/05/2021
|
Tiziana Life Sciences says Accustem Sciences business will be spin out on Nasdaq
- Tiziana Life Sciences PLC (NASDAQ:TLSA, LON:TILS) said it plans to list its diagnostics business Accustem Sciences on the Nasdaq stock market in the US after its demerger and the distribution of new stock to Tiziana shareholders. “The board of directors of Accustem has resolved that the Nasdaq listing venue is more appropriate to the nature of Accustem's business,” a short statement read.
- 04/13/2021
|
Tiziana Life says breast cancer prognostic business Accustem Sciences to list on Nasdaq
- Tiziana Life Sciences plc (LON:TILS NASDAQ:TLSA) said its former subsidiary, Accustem Sciences Limited intends to list on Nasdaq. The listing will follow shortly after the completion of the distribution of shares in Accustem to Tiziana's shareholders and reflects a belief by the directors that Nasdaq is the most appropriate market given the nature of Accustem's business.
- 04/13/2021
|
Tiziana Life says breast cancer diagnostic business Accustem Sciences to list on Nasdaq
- Tiziana Life Sciences plc (LON:TILS NASDAQ:TLSA) said its former subsidiary, Accustem Sciences Limited intends to list on Nasdaq. The listing will follow shortly after the completion of the distribution of shares in Accustem to Tiziana's shareholders and reflects a belief by the directors that Nasdaq is the most appropriate market given the nature of Accustem's business.
- 04/13/2021
|
Zacks Small-Cap Research initiates coverage on Tiziana Life Sciences, which it expects to advance foralumab into "multiple clinical trials" this year
- Zacks Small-Cap Research has started coverage on drug developer Tiziana Life Sciences PLC (NASDAQ:TLSA) (LON:TILS), which is advancing three candidates for a variety of indications in autoimmune disease, cancer and coronavirus (COVID-19). Zacks has placed a valuation of US$7.50 per ADR share compared to a current price of US$3 in New York (up over 12% on the day).
- 04/12/2021
|
Tiziana Life Sciences: US investment bank restates its US$8 price and 'buy' recommendation after double dose of good news
- US investment bank B. Riley Financial has reiterated its ‘buy' advice and US$8 a share price target for Tiziana Life Sciences (NASDAQ:TLSA, LON:TILS) after a double dose of good news.
- 03/30/2021
|
Tiziana Life Sciences shares shoot up after receiving FDA sign-off for use nasally administered monoclonal antibody to treat a person with secondary progressive multiple sclerosis
- Shares in Tiziana Life Sciences plc (NASDAQ:TLSA, LON:TILS) shot up 20% after it announced the US regulator has approved the use of its nasally administered monoclonal antibody to treat a person with secondary progressive multiple sclerosis (SPMS). Foralumab will be provided under the Food & Drug Administration's individual patient expanded access protocol overseen by researchers at the Brigham and Women's Hospital (BWH), Harvard.
- 03/30/2021
|
TLSA Stock Price Increased Over 10% Pre-Market: Why It Happened
- The stock price of Tiziana Life Sciences plc (NASDAQ: TLSA) has increased by over 10% pre-market. This is why it happened.
- 03/30/2021
|
Tiziana Life Sciences plc: Accustem Update
- NEW YORK and LONDON, March 30, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences. (NASDAQ: TLSA; LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, is pleased to confirm that, in order to finalise the distribution of shares in Accustem Sciences Limited ("Accustem") to the holders of Tiziana shares in the US via its ADS program, it has recently filed a Form 20-F with the Securities Exchange Commission in the USA (the "SEC"). The Form 20-F (which gives full information about the business of Accustem), can be found at https://sec.report/CIK/0001850767.
- 03/30/2021
|
Tiziana Life Sciences plans phase II trials of nasal antibody treatment in COVID-19 patients
- Tiziana Life Sciences PLC (NASDAQ:TLSA, LON:TILS) is taking its nasally-administered monoclonal antibody (mAB) into phase II clinical trials in people with moderate to severe Coronavirus (COVID-19). This follows an earlier study in Brazil, which showed evidence that Foralumab reduced pulmonary and systemic inflammation and was well tolerated.
- 03/30/2021
|
Tiziana Life Sciences planning phase II clinical trial of monoclonal antibody treatment in patients with moderate to severe COVID-19
- Tiziana Life Sciences PLC (NASDAQ:TLSA, LON:TILS) is taking its nasally-administered monoclonal antibody (mAB) into phase II clinical trials in people with moderate to severe COVID-19. This follows an earlier study in Brazil, which showed evidence that Foralumab reduced pulmonary and systemic inflammation and was well tolerated.
- 03/30/2021
|
Updated - Gabriele Cerrone, Chairman of Tiziana Life Sciences to give interview on Bloomberg Television US at 1:50 PM ET Tomorrow, 30 March 2021
- NEW YORK and LONDON, March 29, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences (NASDAQ: TLSA; LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, clarifies that its Chairman and Founder, Gabriele Cerrone, will be giving an interview on Bloomberg Television on Tuesday, 30 March 2021 at 1.50 p.m. US Eastern Standard Time (6.50 p.m. London) as part of the Bloomberg Markets Show.
- 03/29/2021
|
Tiziana Life Sciences plc ("Tiziana" or the "Company") - Gabriele Cerrone, Chairman of Tiziana Life Sciences, to give interview on Bloomberg Television US at 1:20 PM ET Today
- NEW YORK and LONDON, March 29, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences. (NASDAQ: TLSA; LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, announces that the Chairman and founder, Gabriele Cerrone, will give an interview on Bloomberg Television on Monday, 29 March 2021 at 1.20 p.m. US Eastern Standard Time (6.20 p.m. London) as part of the Bloomberg Surveillance Show.
- 03/29/2021
|
Tiziana Life Sciences Interview to Air on Bloomberg Television US on The RedChip Money Report
- NEW YORK and LONDON, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences (NASDAQ: TLSA; LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, today announced that an interview with its CEO, Dr Kunwar Shailubhai, will air on The RedChip Money Report on Bloomberg Television on Saturday, February 27, 2021 at 7 p.m. local time across the United States and on the Bloomberg Network in Europe on Sunday, February 28, 2021 at 6 p.m. local time. The RedChip Money Report airs on Bloomberg Television U.S. on Saturdays at 7 p.m. local time in 73M homes and on the Bloomberg Network in Europe in 100M homes at 6 p.m. local time on Sundays.
- 02/26/2021
|
Tiziana Life Sciences to present at BIO CEO & Investor online conference
- Tiziana Life Sciences PLC (LON:TILS, NASDAQ:TLSA) said it is presenting at the BIO CEO & Investor Digital Conference. The conference starts today and runs until Thursday.
- 02/16/2021
|
Proactive news headlines: Iconic Labs, Silence Therapeutics, Chaarat Gold, Tiziana Life Sciences.
- Iconic Labs PLC (LON:ICON), a multidivisional new media and technology business, announced that it has appointed Sarah Dees as its chief executive officer and an executive director with immediate effect. The group noted that Dees has a wealth of management and fundraising experience across a variety of sectors including financial technology, banking, live events and natural resources.
- 02/07/2021
|
Tiziana Life Sciences plc ("Tiziana" or the "Company") - Appointment of Director
- NEW YORK and LONDON, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA / LSE: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, today announces the appointment of Dr. Thomas Adams, Ph.D. as an executive director.
- 02/05/2021
|
Tiziana (TLSA) Posts Positive Data on Nasal COVID-19 Antibody
- Tiziana (TLSA) reports positive data from a study investigating its anti-CD3 human monoclonal antibody, foralumab (nasally administered) for treating COVID-19 patients in Brazil. Shares up.
- 02/03/2021
|
Tiziana Life Sciences CEO Discusses COVID-19 Trial Data in Exclusive Interview
- NEW YORK and LONDON, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ:TLSA/LSE:TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, today announced an interview with Dr. Kunwar Shailubhai, CEO and CSO, is now available.
- 02/03/2021
|
TLSA Stock Price Increases Over 40% Pre-Market: Why It Happened
- The stock price of Tiziana Life Sciences (NASDAQ: TLSA) increased by over 40% pre-market as of 6:05 AM ET. This is why it happened.
- 02/02/2021
|
Tiziana Reports Positive Data from the Clinical Study of Nasal Administration with Foralumab, its proprietary fully human anti-CD3 monoclonal antibody, in COVID-19 Patients in Brazil
- NEW YORK and LONDON, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, reports positive data from the exploratory clinical study in Brazil investigating nasally administered Foralumab, its proprietary anti-CD3 human monoclonal antibody, either alone or in combination with orally administered dexamethasone (“Dexa”) in COVID-19 patients. The clinical study was completed in collaboration with scientific teams at the Harvard Medical School (Boston, USA), and INTRIALS, a full-service Latin American CRO based in São Paulo, Brazil.
- 02/02/2021
|
Tiziana Life Sciences plc ("Tiziana" or the "Company") - Tiziana Files Registration Statement on Form F-3 with U.S. Securities and Exchange Commission
- NEW YORK and LONDON, Jan. 27, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, today announces that it has filed a “universal” shelf registration statement on Form F-3 (File No. 333-252441) (the "Registration Statement") with the U.S. Securities and Exchange Commission ("SEC") in relation to up to US$250,000,000 in market value of its securities.
- 01/27/2021
|
Tiziana Life Sciences to Participate in a Fireside Chat at B. Riley Virtual Oncology Investor Conference on 21 January 2021 at 3 pm ET/8 pm GMT
- NEW YORK and LONDON, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announced its CEO and CSO, Dr. Kunwar Shailubhai, will participate in a fireside chat via a video link on Thursday 21 January 2021 at 3 pm ET / 8 pm GMT to provide updates on the Company.
- 01/20/2021
|
Tiziana Life Sciences plc ("Tiziana" or the "Company") - AIM Delisting and Admission to the Standard Listing Segment of Main Market
- NEW YORK and LONDON, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, today provided a further update with respect to the cancellation of admission of its Ordinary Shares to trading on AIM and admission to listing of its ordinary shares (the "Ordinary Shares") on the standard listing segment of the Official List of the Financial Conduct Authority ("FCA") (the "Official List") and admission to trading on the main market for listed securities (the "Main Market") of London Stock Exchange plc (the "London Stock Exchange") (together, "Admission").
- 01/20/2021
|
Tiziana announces appointment of Dr Neil Graham MBBS, MD, MPH as Chief Medical Officer
- NEW YORK and LONDON, Jan. 13, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, announces the appointment of Dr Neil Graham MBBS, MD, MPH as Chief Medical Officer.
- 01/13/2021
|
Tiziana Life Sciences to participate at J.P. Morgan Healthcare Conference 2021
- NEW YORK and LONDON, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, today announced that it is participating in the J.P. Morgan 39th Annual Healthcare Conference 2021.
- 01/11/2021
|
Tiziana Life Sciences to Present at Biotech Showcase Digital 2021
- NEW YORK and LONDON, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, today announced that it is participating in Biotech Showcase™ 2021 and providing an on-demand company presentation. Registered attendees to Biotech Showcase can now access recorded company presentations prior to the actual event. 24x7 on-demand access allows attendees to view presentations at their convenience, avoiding conflicts with busy meeting schedules during the main event week.
- 01/11/2021
|
Tiziana Life Sciences plc ("Tiziana" or the "Company") - Tiziana announces completion of the clinical trial with nasally administered Foralumab, its proprietary fully human anti-CD3 monoclonal antibody, for the treatment of COVID-19 patients in Brazil
- NEW YORK and LONDON, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, announces the completion of its clinical study in Brazil investigating nasally administered Foralumab, its proprietary human monoclonal antibody, either alone or in combination with orally administered dexamethasone in COVID-19 patients.
- 01/04/2021
|
Tiziana Life Sciences PLC (“Tiziana” or “the Company”) - Publication of Prospectus
- This announcement is an advertisement and not a prospectus. Neither this announcement nor anything contained herein shall form the basis of, or be relied upon in connection with, any offer or commitment whatsoever in any jurisdiction. Investors should not purchase any transferable securities referred to in this announcement except on the basis of information contained in the prospectus (the "Prospectus") in its final form that is published by Tiziana Life Sciences plc in connection with the admission of the Company's ordinary shares (the "Ordinary Shares") to listing on the standard segment of the Official List of the Financial Conduct Authority (the "FCA") and to trading on the main market for listed securities (the "Main Market") of London Stock Exchange plc (the "London Stock Exchange"). This announcement is not an offer to sell, or a solicitation of an offer to acquire, securities in the United States, Australia, Canada, Japan or in any other jurisdiction.
- 12/18/2020
|
Tiziana Life Sciences PLC (“Tiziana” or “the Company”) - Notification of proposed admission to the Main Market and cancellation of trading on AIM
- LONDON and NEW YORK, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces it has applied to list its ordinary shares ("Ordinary Shares") on the standard listing segment of the Official List of the Financial Conduct Authority (“FCA”) (the "Official List") and admission to trading on the London Stock Exchange plc's (the "London Stock Exchange") main market ("Main Market") for listed securities (together, "Admission"). The Board has taken this decision as it believes that a standard listing will afford Tiziana greater flexibility in pursuing its strategy as an international company.
- 12/17/2020
|
Westwater Resources Is a Creative Bet on Electric Vehicles
- Westwater Resources is a natural resources mining company. But WWR stock is also an interesting way to invest in the electric vehicle wave.
- 12/08/2020
|
Tiziana Life Sciences to Host Investor Update Call on 2 December 2020 at 4:15 p.m. ET
- NEW YORK and LONDON, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announced its CEO and CSO Dr. Kunwar Shailubhai will host a conference call on Wednesday, 2 December 2020 at 4:15 p.m. ET to provide updates on the Company. Dr. Shailubhai will provide updates on the Company's proposed move from AIM to the Standard Segment of the Main Market of the London Stock Exchange, ongoing clinical trials, as well as other recent developments in Tiziana Life Sciences.
- 12/01/2020
|
Tiziana Life Sciences PLC ("Tiziana" or the "Company") - PDMR Dealing
- LONDON and NEW YORK, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that it has been notified that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman has a beneficial interest, purchased 45,000 ordinary shares of 3p each in the market at a price of 84p per share.
- 11/18/2020
|
Tiziana Life Sciences announces collaboration with Parexel Biotech to conduct phase 1b/2 clinical trial in patients with Crohn's Disease
- First Ever Study with take-home capsules of Foralumab , a Fully Human Anti-CD3 Monoclonal Antibody
- 11/11/2020
|
Tiziana Enters Human Trials for Covid-19 Treatment
- Nov.02 -- Tiziana Life Sciences PLC is launching a clinical trial in Brazil involving humans where they will be treated with a nasally administered Foralumab, a monoclonal antibody. Gabriele Cerrone, the chief executive officer, speaks on "Bloomberg Markets.
- 11/02/2020
|
Tiziana Announces Initiation of Clinical Trial with Covid-19 Patients in Brazil with Nasally Administered Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody
- Tiziana Life Sciences plc
- 11/02/2020
|
Tiziana Life Sciences Announces Timetable of Demerger of Accustem (for holders of Tiziana ADRs)
- NEW YORK and LONDON, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that it is confirming the timetable for the Accustem Sciences Limited ("Accustem") demerger (the "Demerger") for holders of the Company's American Depositary Receipts (“ADRs”).
- 10/27/2020
|
